arrow
M

Maria Chondrogianni

second department of neurology
H指数:14
被引数:1,057

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness and safety of sumatriptan 85 mg/naproxen sodium 500 mg combination for acute migraine: prospective real-world evidence from the GRASP Study Group

曲普坦85 mg/萘普生钠500 mg联合治疗急性偏头痛的疗效与安全性:GRASP研究小组的前瞻性真实世界证据

2026-07-300
OA
Comparing the Efficacy and Safety of Anti-CGRP Monoclonal Antibodies Versus Topiramate for Migraine Prophylaxis: Six-Month, Real-World, Intention-to-Treat Retrospective Evidence from the GRASP Study Group

比较抗CGRP单克隆抗体与托吡酯在偏头痛预防中的疗效与安全性:GRASP研究小组提供的为期六个月、真实世界、意向性治疗回顾性证据

2026-04-050
OAAI
Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group

Eptinezumab预防难以治疗的偏头痛: 来自GRASP研究组的前瞻性,六个月,真实世界的多中心证据

2026-01-230
OAAI
Gout flares following acute stroke: a single-center cohort and a systematic review/meta-analysis

痛风发作继发于急性卒中:一项单中心队列研究及系统评价/荟萃分析

2025-10-150
OA
Spontaneous Multiple Cervical Artery Dissections Detected with High-Resolution MRI: A Prospective, Case-Series Study

自发性多发性颈动脉夹层经高分辨率MRI检测:一项前瞻性病例系列研究

2025-10-010
OA
Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis

GLP-1和双重GIP/GLP-1受体激动剂在特发性颅内高压中的有效性与安全性:一项系统评价和Meta分析

2025-09-120
PREAI
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group

暂停和重新启动Fremanezumab治疗对预防难治性偏头痛的24个月连续治疗效果:GRASP研究组的回顾性、多中心、真实世界数据

2025-08-140
PREAI
Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: A case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence

cenobamate 在发育性和癫痫性脑病以及全身性癫痫中的应用:一例伴有肌阵挛-无张力发作的癫痫病例报告及当前证据的系统综述

2025-07-010
OAAI
Fibrinogen time course in acute ischemic stroke patients treated with intravenous thrombolysis with alteplase or tenecteplase

纤维蛋白原时间过程在用阿替普酶或替奈普酶进行静脉溶栓治疗的急性缺血性卒中患者中

2025-06-150
PRE
Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications

脂蛋白(a)作为卒中生物标志物:病理生理通路和治疗意义

2025-04-250
OA
Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke
2024-10-080
PRE